Developer docs
API playgroundTry for free, no card

Search company profiles

Aerogen

Full company profile

uuid0000oaj

Namestring
Aerogen
Legal namestring
Aerogen Ltd
Websiteurl
aerogen.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Aerogen is a privately held Irish medical device company founded in 1997-1998 by John Power in Galway, Ireland, that develops vibrating mesh nebuliser technology for high-performance aerosol drug delivery in acute care settings. Its core product platform, centered on the Aerogen Solo single-patient-use nebuliser, delivers approximately four times more medication to the lungs than conventional jet nebulisers across invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patient modes, supported by more than 300 international patents and 300 peer-reviewed publications. The company is the designated partner of choice for the world's leading mechanical ventilator manufacturers and distributes through direct sales in major markets plus an exclusive distributor network across more than 80 countries, with manufacturing in Galway and Shannon (Ireland) and regional hubs in Chicago, New Delhi, Tokyo, Düsseldorf, and Dubai.

Aerogen generates revenue primarily through hardware sales of its nebuliser devices and accessories (Solo, Ultra, Go, Pro, CNTS, controllers), with US channel access secured through GPO contracts with Premier and Vizient. A complementary specialty pharmaceutical revenue stream is being built through Aerogen Pharma, a US-based clinical-stage subsidiary developing inhaled drug and biologic-device combinations, including neonatal respiratory distress syndrome surfactant delivery in partnership with the Bill & Melinda Gates Foundation and Nuance Pharma in China. The company serves acute care hospitals and ICUs as its primary end market, with secondary segments in emergency and respiratory care, neonatal care, and ventilator OEMs as integration partners. Customers include leading hospital systems and GPOs, while collaborations with CanSinoBIO (world's first inhaled COVID-19 vaccine), Synairgen (inhaled interferon-beta), UNICEF, Tyndall National Institute, and CÚRAM demonstrate a broader ecosystem of public health, vaccine delivery, and academic research partnerships.

Short descriptiontext

Aerogen is an Ireland-based medical device company that develops vibrating mesh nebuliser technology for acute care aerosol drug delivery to hospitals, ICUs, and ventilator OEMs across more than 80 countries. It sells the Aerogen Solo platform, supports it with over 300 patents and clinical publications, and is extending into drug-device combinations through its Aerogen Pharma subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersGalway, Ireland
HQ citystring
Galway
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aerosol drug delivery, vibrating mesh nebulizers, respiratory care devices, acute care nebulization, ventilation therapy devices
Industry3 codes
PRIMARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAG
Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Respiratory Care Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales - Nebulisers
TypeHardware Sales
Description

Aerogen generates revenue through the sale of its vibrating mesh nebuliser devices including Aerogen Solo, Aerogen Ultra, Aerogen Go, and related accessories. Products are sold directly and through distributor networks globally to healthcare facilities.

aerogen.com
2Aerogen Pharma - Drug-Device Combinations
TypeLicensing Royalties
Description

Aerogen Pharma, a US-based clinical-stage specialty pharmaceutical company, is developing inhaled drug/biologic and device combination products including treatments for neonatal respiratory distress syndrome.

aerogen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Aerogen Pharma
Description

US-based clinical-stage specialty pharmaceutical company developing inhaled drug/biologic and device combinations for acute and critically ill patients, including treatments for neonatal respiratory distress syndrome (RDS).

aerogen.com
Core offering1 text field

Aerogen designs, manufactures, and sells vibrating mesh nebuliser devices used by hospitals and intensive care units for high-performance aerosol drug delivery across the full respiratory care journey (invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patients). Its wholly owned subsidiary Aerogen Pharma develops inhaled drug/device combination products targeting acute and neonatal respiratory conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4x more medication delivered to lungs vs jet nebulisers during NIV
+4 more records
Product overview1 text field

Aerogen offers a portfolio of vibrating mesh nebulizer products for acute care aerosol drug delivery. The core product is the Aerogen Solo, a single-patient-use vibrating mesh nebulizer that can be used throughout a patient's entire respiratory journey across different ventilation modes (IMV, NIV, HF, and self-ventilating). Supporting products include the Aerogen Ultra handheld inhalation device, Aerogen Go, Aerogen Pro, the Aerogen Continuous Nebulisation Tube Set (CNTS) for continuous therapy, and Controllers and Accessories. The company also operates Aerogen Pharma as a clinical-stage specialty pharmaceutical division focused on inhaled drug/biologic and device combinations.

Product and service7 records
1Aerogen Solo
CategoryVibrating Mesh Nebuliser
Description

Single-patient-use vibrating mesh nebuliser that delivers aerosolised medication across invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patient scenarios for up to 28 days intermittent or 7 days continuous use; intended for hospital ICU and acute care use.

2Aerogen Ultra
CategoryHandheld Vibrating Mesh Nebuliser
Description

Handheld vibrating mesh nebuliser used in conjunction with the Aerogen Solo to deliver inhalation treatment to spontaneously breathing and emergency department patients.

3Aerogen Go
CategoryPortable Vibrating Mesh Nebuliser
Description

Portable vibrating mesh nebuliser for aerosol drug delivery within the Aerogen product lineup, intended for clinical respiratory therapy use.

4Aerogen Pro
CategoryProfessional Vibrating Mesh Nebuliser
Description

Professional-grade vibrating mesh nebuliser within Aerogen's portfolio of acute care aerosol drug delivery devices.

5Aerogen Continuous Nebulisation Tube Set (CNTS)
CategoryNebuliser Accessory
Description

Tube set accessory that enables continuous nebulisation therapy when used with the Aerogen Solo system.

6Aerogen Controllers and Accessories
CategoryNebuliser Accessories
Description

Power controllers and accessories that operate and support the Aerogen vibrating mesh nebuliser product family in clinical settings.

7Aerogen Pharma Drug-Device Combination Products
CategoryInhaled Drug-Device Combinations
Description

Clinical-stage inhaled drug and biologic/device combination products developed by the wholly owned subsidiary Aerogen Pharma for treatment of neonatal respiratory distress syndrome and other acute respiratory conditions in critically ill patients.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to advance inhaled therapy for severe respiratory infections. Synairgen's SNG001 (inhaled interferon-beta) being evaluated with Aerogen's nebuliser technology in global Phase 2 INVENT clinical study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Landmark development and commercial supply partnership for world's first inhaled Covid-19 vaccine delivery using Aerogen's vibrating mesh nebuliser technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aerogen Pharma entered exclusive agreements with Nuance Pharma to advance treatment of respiratory distress syndrome in premature infants in China.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership for Switzerland. ANANDIC (Anesthesia and Intensive Care & Cardiology) is a leading Swiss market company with 3 locations providing customer support and service.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

New distributor partnership for Mexico to expand market presence and customer support in Mexican healthcare market.

6Acertys
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor partnership for Belgium to support and service Aerogen users in the Belgian market.

aerogen.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Group purchasing organization awarded Aerogen respiratory therapy: medication delivery and bronchial hygiene agreement for US healthcare members.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Vizient awarded Aerogen contract for medication delivery to member healthcare organizations across the US.

Strategic tierRegionalTypeStrategic or Co-development Partner
Description

Collaboration with CÚRAM (Centre for Research in Medical Devices) to alleviate acute respiratory failure in COVID patients.

Strategic tierRegionalTypeStrategic or Co-development Partner
Description

€300k research collaboration agreement with Tyndall for technology development and research initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aerogen supports global vaccine equity and neonatal health through UNICEF partnerships and initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Bill & Melinda Gates Foundation for development of low-cost surfactant for premature babies with respiratory distress syndrome.

Strategic tierRegionalTypeTechnology or Integration
Description

Continued partnership with Druid for integrated solutions in respiratory care.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specializes in nebuliser systems and inhaled drug delivery for respiratory diseases including cystic fibrosis and COPD. Directly comparable to Aerogen in core product category of aerosol drug delivery, with overlapping hospital and home-care customer bases.

TypeBroad incumbent
Description

Large incumbent in respiratory care and ventilation offering nebulisers, CPAP/BiPAP, and hospital respiratory solutions. Overlaps with Aerogen in hospital aerosol drug delivery but as part of a much broader portfolio.

TypeBroad incumbent
Description

Global leader in respiratory humidification, high-flow therapy, and neonatal care products sold into the same ICU and NICU customers Aerogen serves. Comparable in acute-care hospital channels and increasingly in the high-flow therapy segment adjacent to Aerogen's HF modality.

TypeBroad incumbent
Description

Manufactures respiratory care products including nebulisers and aerosol delivery devices used in acute-care hospitals. Sells into the same ICU/critical care channels as Aerogen, with a broader single-use device portfolio.

5Omron Healthcare
TypeDirect peer
Description

Major manufacturer of nebuliser devices for asthma, COPD, and respiratory conditions, with both compressor and mesh technologies. Direct competitor in aerosol drug delivery, although Omron is more weighted to home/consumer use than Aerogen's acute-care focus.

TypeEmerging player
Description

Specializes in high-flow therapy systems for respiratory distress, overlapping with Aerogen's HF modality segment. Sells into the same acute-care hospital channel and increasingly competes for aerosol delivery during high-flow treatment.

TypeDirect peer
Description

European manufacturer of respiratory care products including nebulisers and breathing circuits. Direct competitor in hospital aerosol drug delivery with comparable ICU customer base across EMEA.

TypeEmerging player
Description

Develops inhaled drug-device combinations and nebuliser platforms for respiratory disease. Comparable to Aerogen Pharma's inhaled drug/biologic development strategy, especially in dry-powder and smart nebuliser technologies.

TypeOthers
Description

Leading ventilator OEM whose systems are explicitly integrated with Aerogen nebulisers. Highly relevant as an OEM channel partner and a key distribution conduit for Aerogen Solo in ICU settings globally.

TypeDirect peer
Description

Manufactures respiratory care products including a portfolio of nebulisers for clinical and home use. Competitor in the aerosol drug delivery category with overlapping acute and post-acute care customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aerogen

Respiratory Care Medical Devicesaerogen.com

Aerogen is an Ireland-based medical device company that develops vibrating mesh nebuliser technology for acute care aerosol drug delivery to hospitals, ICUs, and ventilator OEMs across more than 80 countries. It sells the Aerogen Solo platform, supports it with over 300 patents and clinical publications, and is extending into drug-device combinations through its Aerogen Pharma subsidiary.

What Aerogen does

Aerogen is a privately held Irish medical device company founded in 1997-1998 by John Power in Galway, Ireland, that develops vibrating mesh nebuliser technology for high-performance aerosol drug delivery in acute care settings. Its core product platform, centered on the Aerogen Solo single-patient-use nebuliser, delivers approximately four times more medication to the lungs than conventional jet nebulisers across invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patient modes, supported by more than 300 international patents and 300 peer-reviewed publications. The company is the designated partner of choice for the world's leading mechanical ventilator manufacturers and distributes through direct sales in major markets plus an exclusive distributor network across more than 80 countries, with manufacturing in Galway and Shannon (Ireland) and regional hubs in Chicago, New Delhi, Tokyo, Düsseldorf, and Dubai.

Aerogen generates revenue primarily through hardware sales of its nebuliser devices and accessories (Solo, Ultra, Go, Pro, CNTS, controllers), with US channel access secured through GPO contracts with Premier and Vizient. A complementary specialty pharmaceutical revenue stream is being built through Aerogen Pharma, a US-based clinical-stage subsidiary developing inhaled drug and biologic-device combinations, including neonatal respiratory distress syndrome surfactant delivery in partnership with the Bill & Melinda Gates Foundation and Nuance Pharma in China. The company serves acute care hospitals and ICUs as its primary end market, with secondary segments in emergency and respiratory care, neonatal care, and ventilator OEMs as integration partners. Customers include leading hospital systems and GPOs, while collaborations with CanSinoBIO (world's first inhaled COVID-19 vaccine), Synairgen (inhaled interferon-beta), UNICEF, Tyndall National Institute, and CÚRAM demonstrate a broader ecosystem of public health, vaccine delivery, and academic research partnerships.

Aerogen firmographics

Firmographics
Name
Aerogen
Legal name
Aerogen Ltd
Website
https://aerogen.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Aerogen is an Ireland-based medical device company that develops vibrating mesh nebuliser technology for acute care aerosol drug delivery to hospitals, ICUs, and ventilator OEMs across more than 80 countries. It sells the Aerogen Solo platform, supports it with over 300 patents and clinical publications, and is extending into drug-device combinations through its Aerogen Pharma subsidiary.
Ownership category
akta.pro rank

Aerogen industry classification

Industry
Product category
Respiratory Care Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAG
Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Aerosol drug delivery
  • Vibrating mesh nebulizers
  • Respiratory care devices
  • Acute care nebulization
  • Ventilation therapy devices

Where Aerogen is headquartered

Location

Headquarters

HQ city
Galway
HQ country
Ireland
HQ region
Europe

Offices7 records

Markets served

Aerogen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Medical Device Sales - Nebulisers: Aerogen generates revenue through the sale of its vibrating mesh nebuliser devices including Aerogen Solo, Aerogen Ultra, Aerogen Go, and related accessories. Products are sold directly and through distributor networks globally to healthcare facilities.
  2. Aerogen Pharma - Drug-Device Combinations: Aerogen Pharma, a US-based clinical-stage specialty pharmaceutical company, is developing inhaled drug/biologic and device combination products including treatments for neonatal respiratory distress syndrome.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Aerogen product offering

Product offering

Core offering

Aerogen designs, manufactures, and sells vibrating mesh nebuliser devices used by hospitals and intensive care units for high-performance aerosol drug delivery across the full respiratory care journey (invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patients). Its wholly owned subsidiary Aerogen Pharma develops inhaled drug/device combination products targeting acute and neonatal respiratory conditions.

Product overview

Aerogen offers a portfolio of vibrating mesh nebulizer products for acute care aerosol drug delivery. The core product is the Aerogen Solo, a single-patient-use vibrating mesh nebulizer that can be used throughout a patient's entire respiratory journey across different ventilation modes (IMV, NIV, HF, and self-ventilating). Supporting products include the Aerogen Ultra handheld inhalation device, Aerogen Go, Aerogen Pro, the Aerogen Continuous Nebulisation Tube Set (CNTS) for continuous therapy, and Controllers and Accessories. The company also operates Aerogen Pharma as a clinical-stage specialty pharmaceutical division focused on inhaled drug/biologic and device combinations.

Differentiator

Problem solved

Functional benefit

Brands

  • Aerogen Pharma: US-based clinical-stage specialty pharmaceutical company developing inhaled drug/biologic and device combinations for acute and critically ill patients, including treatments for neonatal respiratory distress syndrome (RDS).

Products and services

  • Aerogen Solo Single-patient-use vibrating mesh nebuliser that delivers aerosolised medication across invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patient scenarios for up to 28 days intermittent or 7 days continuous use; intended for hospital ICU and acute care use.
  • Aerogen Ultra Handheld vibrating mesh nebuliser used in conjunction with the Aerogen Solo to deliver inhalation treatment to spontaneously breathing and emergency department patients.
  • Aerogen Go Portable vibrating mesh nebuliser for aerosol drug delivery within the Aerogen product lineup, intended for clinical respiratory therapy use.
  • Aerogen Pro Professional-grade vibrating mesh nebuliser within Aerogen's portfolio of acute care aerosol drug delivery devices.
  • Aerogen Continuous Nebulisation Tube Set (CNTS) Tube set accessory that enables continuous nebulisation therapy when used with the Aerogen Solo system.
  • Aerogen Controllers and Accessories Power controllers and accessories that operate and support the Aerogen vibrating mesh nebuliser product family in clinical settings.
  • Aerogen Pharma Drug-Device Combination Products Clinical-stage inhaled drug and biologic/device combination products developed by the wholly owned subsidiary Aerogen Pharma for treatment of neonatal respiratory distress syndrome and other acute respiratory conditions in critically ill patients.

Quantifiable outcome

  • 4x more medication delivered to lungs vs jet nebulisers during NIV
  • +4 more outcomes

Companies that use Aerogen

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Aerogen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aerogen partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and regional.

  • SynairgencoreStrategic or Co-development PartnerStrategic partnership to advance inhaled therapy for severe respiratory infections. Synairgen's SNG001 (inhaled interferon-beta) being evaluated with Aerogen's nebuliser technology in global Phase 2 INVENT clinical study.
  • CanSinoBIOcoreStrategic or Co-development PartnerLandmark development and commercial supply partnership for world's first inhaled Covid-19 vaccine delivery using Aerogen's vibrating mesh nebuliser technology.
  • Nuance PharmacoreStrategic or Co-development PartnerAerogen Pharma entered exclusive agreements with Nuance Pharma to advance treatment of respiratory distress syndrome in premature infants in China.
  • ANANDIC Medical Systems AGregionalChannel Partner/ Reseller/ DistributorDistribution partnership for Switzerland. ANANDIC (Anesthesia and Intensive Care & Cardiology) is a leading Swiss market company with 3 locations providing customer support and service.
  • Grupo MoraviregionalChannel Partner/ Reseller/ DistributorNew distributor partnership for Mexico to expand market presence and customer support in Mexican healthcare market.
  • AcertysregionalChannel Partner/ Reseller/ DistributorDistributor partnership for Belgium to support and service Aerogen users in the Belgian market.
  • Premier, Inc.coreChannel Partner/ Reseller/ DistributorGroup purchasing organization awarded Aerogen respiratory therapy: medication delivery and bronchial hygiene agreement for US healthcare members.
  • VizientcoreChannel Partner/ Reseller/ DistributorVizient awarded Aerogen contract for medication delivery to member healthcare organizations across the US.
  • CÚRAMregionalStrategic or Co-development PartnerCollaboration with CÚRAM (Centre for Research in Medical Devices) to alleviate acute respiratory failure in COVID patients.
  • Tyndall National InstituteregionalStrategic or Co-development Partner€300k research collaboration agreement with Tyndall for technology development and research initiatives.
  • UNICEFcoreStrategic or Co-development PartnerAerogen supports global vaccine equity and neonatal health through UNICEF partnerships and initiatives.
  • Bill & Melinda Gates FoundationcoreStrategic or Co-development PartnerPartnership with Bill & Melinda Gates Foundation for development of low-cost surfactant for premature babies with respiratory distress syndrome.
  • DruidregionalTechnology or IntegrationContinued partnership with Druid for integrated solutions in respiratory care.

Scale indicators8 records

Recent moves9 records

Expansion highlights7 records

Aerogen competitors and assessment

Company assessment

Direct peers

  • PARI Pharma: Specializes in nebuliser systems and inhaled drug delivery for respiratory diseases including cystic fibrosis and COPD. Directly comparable to Aerogen in core product category of aerosol drug delivery, with overlapping hospital and home-care customer bases.
  • Omron Healthcare: Major manufacturer of nebuliser devices for asthma, COPD, and respiratory conditions, with both compressor and mesh technologies. Direct competitor in aerosol drug delivery, although Omron is more weighted to home/consumer use than Aerogen's acute-care focus.
  • Intersurgical: European manufacturer of respiratory care products including nebulisers and breathing circuits. Direct competitor in hospital aerosol drug delivery with comparable ICU customer base across EMEA.
  • Drive DeVilbiss Healthcare: Manufactures respiratory care products including a portfolio of nebulisers for clinical and home use. Competitor in the aerosol drug delivery category with overlapping acute and post-acute care customers.

Broad incumbents

  • Philips Respironics: Large incumbent in respiratory care and ventilation offering nebulisers, CPAP/BiPAP, and hospital respiratory solutions. Overlaps with Aerogen in hospital aerosol drug delivery but as part of a much broader portfolio.
  • Fisher & Paykel Healthcare: Global leader in respiratory humidification, high-flow therapy, and neonatal care products sold into the same ICU and NICU customers Aerogen serves. Comparable in acute-care hospital channels and increasingly in the high-flow therapy segment adjacent to Aerogen's HF modality.
  • Teleflex: Manufactures respiratory care products including nebulisers and aerosol delivery devices used in acute-care hospitals. Sells into the same ICU/critical care channels as Aerogen, with a broader single-use device portfolio.

Emerging players

  • Vapotherm: Specializes in high-flow therapy systems for respiratory distress, overlapping with Aerogen's HF modality segment. Sells into the same acute-care hospital channel and increasingly competes for aerosol delivery during high-flow treatment.
  • Vectura Group (now Philip Morris International): Develops inhaled drug-device combinations and nebuliser platforms for respiratory disease. Comparable to Aerogen Pharma's inhaled drug/biologic development strategy, especially in dry-powder and smart nebuliser technologies.

Others

  • Hamilton Medical: Leading ventilator OEM whose systems are explicitly integrated with Aerogen nebulisers. Highly relevant as an OEM channel partner and a key distribution conduit for Aerogen Solo in ICU settings globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Aerogen social profiles

Digital presence

Aerogen compliance and trust

Trust signal

Compliance3 records

Aerogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aerogen leadership team

Management profile

Number of profiles

Profiles2 records

Aerogen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aerogen funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aerogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aerogen

What does Aerogen do?

Aerogen designs, manufactures, and sells vibrating mesh nebuliser devices used by hospitals and intensive care units for high-performance aerosol drug delivery across the full respiratory care journey (invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patients). Its wholly owned subsidiary Aerogen Pharma develops inhaled drug/device combination products targeting acute and neonatal respiratory conditions.

Is Aerogen a public or private company?

Aerogen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Aerogen founded?

Aerogen was founded in 1998. It employs 501 to 1,000 people.

Where is Aerogen based?

Aerogen is headquartered in Galway, Ireland, in the Europe region.

How does Aerogen make money?

Two revenue lines are on record. Medical Device Sales - Nebulisers are the primary driver. The others are aerogen Pharma - Drug-Device Combinations.

Who are Aerogen's main competitors?

Direct peers on record are PARI Pharma, Omron Healthcare, Intersurgical and Drive DeVilbiss Healthcare. Broad incumbents are Philips Respironics, Fisher & Paykel Healthcare and Teleflex. Emerging players are Vapotherm and Vectura Group (now Philip Morris International). Hamilton Medical is listed as an others.

Does Aerogen have an API?

No public API is recorded for Aerogen.

What industry is Aerogen in?

Aerogen's product category is Respiratory Care Medical Devices. Its primary akta.pro industry code is HLAHAIAJ, Nebulizers & Aerosol Drug Delivery Systems, with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 3391 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireWorld-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.On October 25, Shanghai became the first city to initiate inhaled COVID-19 booster vaccination for adults, using the Aerogen-CanSinoBIO inhaled vaccine Convidecia Air. The vaccine received Emergency Use Authorization from China's NMPA in 2022, and clinical trials showed it generated stronger immune responses than inactivated vaccine boosters.DrugdeliverybusinessAerosol drug delivery company Aerogen to expand in IrelandAerogen announced a $308.5 million investment to expand operations in Ireland, creating 725 new jobs over the next decade. The Galway-based company, Ireland's largest indigenous medtech firm, expects to add jobs at its Parkmore and Shannon sites, increasing its global workforce to over 2,000 by 2035.RTE.ieRegional start-up summit planned for GalwayScale Ireland, with Microsoft and ISIF support, will host a regional start-up summit in Galway next month, featuring companies like AMCS and Aerogen. The summit follows a second 'State of Start-ups Survey' on capital, staffing, and taxation, with results published in February. Ireland has over 2,200 indigenous tech start-ups employing 55,000 people.BioWorldCansino partners with Aerogen for inhalable COVID vaccineCansino Biologics partnered with Aerogen to develop an inhalable version of its COVID-19 vaccine Convidecia, combining it with Aerogen's vibrating mesh aerosol technology. The technology delivers up to six times more medication to the lungs than jet nebulizers. Commercial terms were not disclosed.Think Business23 Irish life sciences and medtech firms changing the worldThe Irish Medtech Association highlights 23 Irish life sciences and medtech firms driving innovation in healthcare, noting that the sector has attracted €566m in investments and created 2,300 jobs over the past three years. The article profiles companies such as Aerogen, LetsGetChecked, and SilverCloud Health, detailing their technological advancements, recent funding rounds, and job creation initiatives.Silicon Republic5 recent jobs announcements you might have missedHuawei plans to invest €80m in Irish R&D and hire 110 staff, while Microsoft Ireland adds 200 jobs. Aerogen opens a Shannon facility with 90 hires, and StormHarvester creates 16 roles in Northern Ireland. The article also offers job-search advice.Silicon RepublicIrish medtech Aerogen hiring for 90 new roles in ShannonAerogen is hiring over 90 new staff at its new Shannon manufacturing facility, recruiting across operations, engineering, and quality assurance. The company, which received backing from the Disruptive Technologies Innovation Fund in 2019, has installed equipment in the former Molex building. It plans further investments to support growth and new markets.Silicon RepublicAerogen named 2020 Irish Medtech Company of the YearAerogen won the grand prize at the Irish Medtech Awards, with Medtronic also named a winner. The Galway-based company's product utilisation surpassed 10 million patients and grew over 30% in 2020. It had previously received €9.4m in DTIF funding for exosome therapeutics.RTE.ieGalway firm involved in development of Covid therapiesAerogen, a Galway-based aerosol drug delivery firm, announced a global collaboration to support Covid-19 vaccine and treatment development. Its nebuliser technology is used in hospitals for ventilated patients, and it signed an agreement with Synairgen to deliver SNG001, an inhaled interferon beta, with initial results showing reduced severe disease risk. Several collaborations are in clinical trials, with others planned for moderately and severely ill patients.Think Business10 innovative Galway businesses to watchTen Galway-based innovation businesses are profiled, including Aerogen, Atlantic Therapeutics, and Bluedrop Medical. Aerogen is increasing production by up to 50% to meet global demand, while Atlantic Therapeutics raised €28m ahead of a US market move. The list highlights Galway's growing medtech and digital tech scene.